91 related articles for article (PubMed ID: 1690865)
1. Studies on natural killer cells in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake RJ; Advani S; Gangal SG
Neoplasma; 1990; 37(1):47-53. PubMed ID: 1690865
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
3. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
Cervantes F; Miller JS; McGlave PB
Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
[TBL] [Abstract][Full Text] [Related]
4. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
5. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation.
Schulze A; Schirutschke H; Oelschlägel U; Schmitz M; Füssel M; Wassmuth R; Ehninger G; Bornhäuser M; Platzbecker U
Exp Hematol; 2008 Apr; 36(4):378-89. PubMed ID: 18261840
[TBL] [Abstract][Full Text] [Related]
6. The chemiluminescence response of human natural killer cells. II. Association of a decreased response with low natural killer activity.
Werkmeister J; Helfand S; Roder J; Pross H
Eur J Immunol; 1983 Jun; 13(6):514-20. PubMed ID: 6574914
[TBL] [Abstract][Full Text] [Related]
7. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
[TBL] [Abstract][Full Text] [Related]
8. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis.
Chen X; Woiciechowsky A; Raffegerst S; Schendel D; Kolb HJ; Roskrow M
Br J Haematol; 2000 Dec; 111(3):817-25. PubMed ID: 11122143
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
10. Surface antigen determinants in subpopulations of peripheral blood NK- and T-cells separated by Percoll density fractionation.
Schlesinger M; Lew F; Bekesi JG
J Clin Lab Immunol; 1984 Apr; 13(4):195-202. PubMed ID: 6204054
[TBL] [Abstract][Full Text] [Related]
11. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
Chen J; Schmitt A; Bunjes D; Chen B; Schmitt M
Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactivity of lymphocytes from draining lymph nodes, peripheral blood and tumor infiltrates from oral cancer patients.
Mukhopadhyaya R; Tatake RJ; Krishnan N; Rao RS; Fakih AR; Naik SL; Gangal SG
J Clin Lab Immunol; 1989 Sep; 30(1):21-5. PubMed ID: 2641790
[TBL] [Abstract][Full Text] [Related]
14. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
[TBL] [Abstract][Full Text] [Related]
15. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
16. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
[TBL] [Abstract][Full Text] [Related]
17. Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen.
Phillips JH; Lanier LL
J Immunol; 1986 Mar; 136(5):1579-85. PubMed ID: 2419407
[TBL] [Abstract][Full Text] [Related]
18. Phenotypical and functional analyses of natural killer cells from low NK activity individuals among healthy and patient populations.
Nagao F; Yabe T; Xu M; Okumura K
Nat Immun; 1995 Sep; 14(5-6):225-33. PubMed ID: 8933817
[TBL] [Abstract][Full Text] [Related]
19. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
